BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF GENERAL MEETING
The Company is pleased to announce that, at the General Meeting held today, the resolution put to the meeting was passed by way of a poll.
| Resolution | Votes For | % | Votes Against | % | Votes Withheld1 |
| To approve the continuation of the Company's business as a closed-ended investment trust. | 704,196,309
| 94.06
| 44,493,800
| 5.94
| 21,716
|
1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.
A copy of the resolution has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
28 December 2023
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
T. +44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
